Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
In medical outpatients with high health anxiety, cognitive–behaviour therapy led to bigger improvements than standard care in health anxiety and these improvements were maintained over 5 years of follow-up.
Abstract
Background:
Health anxiety is an under-recognised but frequent cause of distress that is potentially treatable, but there are few studies in secondary care.
Objective:
To determine the clinical effectiveness and cost-effectiveness of a modified form of cognitive–behaviour therapy (CBT) for health anxiety (CBT-HA) compared with standard care in medical outpatients.
Design:
Randomised controlled trial.
Setting:
Five general hospitals in London, Middlesex and Nottinghamshire.
Participants:
A total of 444 patients aged 16–75 years seen in cardiology, endocrinology, gastroenterology, neurology and respiratory medicine clinics who scored ≥ 20 points on the Health Anxiety Inventory (HAI) and satisfied diagnostic requirements for hypochondriasis. Those with current psychiatric disorders were excluded, but those with concurrent medical illnesses were not.
Interventions:
Cognitive–behaviour therapy for health anxiety – between 4 and 10 1-hour sessions of CBT-HA from a health professional or psychologist trained in the treatment. Standard care was normal practice in primary and secondary care.
Main outcome measures:
Primary – researchers masked to allocation assessed patients at baseline, 3, 6, 12, 24 months and 5 years. The primary outcome was change in the HAI score between baseline and 12 months. Main secondary outcomes – costs of care in the two groups after 24 and 60 months, change in health anxiety (HAI), generalised anxiety and depression [Hospital Anxiety and Depression Scale (HADS)] scores, social functioning using the Social Functioning Questionnaire and quality of life using the EuroQol-5 Dimensions (EQ-5D), at 6, 12, 24 and 60 months, and deaths over 5 years.
Results:
Of the 28,991 patients screened over 21 months, 5769 had HAI scores of ≥ 20 points. Improvement in HAI scores at 3 months was significantly greater in the CBT-HA group (mean number of sessions = 6) than in the standard care, and this was maintained over the 5-year period (overall p < 0.0001), with no loss of efficacy between 2 and 5 years. Differences in the generalised anxiety (p = 0.0018) and depression scores (p = 0.0065) on the HADS were similar in both groups over the 5-year period. Gastroenterology and cardiology patients showed the greatest CBT gains. The outcomes for nurses were superior to those of other therapists. Deaths (n = 24) were similar in both groups; those in standard care died earlier than those in CBT-HA. Patients with mild personality disturbance and higher dependence levels had the best outcome with CBT-HA. Total costs were similar in both groups over the 5-year period (£12,590.58 for CBT-HA; £13,334.94 for standard care). CBT-HA was not cost-effective in terms of quality-adjusted life-years, as measured using the EQ-5D, but was cost-effective in terms of HAI outcomes, and offset the cost of treatment.
Limitations:
Many eligible patients were not randomised and the population treated may not be representative.
Conclusions:
CBT-HA is a highly effective treatment for pathological health anxiety with lasting benefit over 5 years. It also improves generalised anxiety and depressive symptoms more than standard care. The presence of personality abnormality is not a bar to successful outcome. CBT-HA may also be cost-effective, but the high costs of concurrent medical illnesses obscure potential savings. This treatment deserves further research in medical settings.
Trial registration:
Current Controlled Trials ISRCTN14565822.
Funding:
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 50. See the NIHR Journals Library website for further project information.
Contents
- Plain English summary
- Scientific summary
- Chapter 1. Introduction to health anxiety
- Chapter 2. Trial methods
- Research objectives
- Patient and public involvement
- Trial summary
- Settings
- Form of randomisation
- Target population and procedure
- Inclusion and exclusion criteria
- Assessments
- Methods of overcoming bias
- Study interventions
- Training and fidelity of intervention
- Standard treatment arm
- Sample size
- Statistical analysis
- Chapter 3. Results
- Chapter 4. Economic evaluation
- Chapter 5. Discussion
- Identification and classification of health anxiety
- Representativeness of sample
- Differences from recent studies
- Meaningful clinical difference in Health Anxiety Inventory scores
- Relevance of findings of personality status
- Implications for health services
- Long-term benefit of cognitive–behaviour therapy for health anxiety
- Interpretation of the economic evaluation
- Chapter 6. Recommendations for further research
- Acknowledgements
- References
- List of abbreviations
About the Series
Article history
The research reported in this issue of the journal was funded by the HTA programme as project number 15/141/02. The contractual start date was in October 2008. The draft report began editorial review in May 2016 and was accepted for publication in February 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Declared competing interests of authors
Paul Salkovskis is Editor-in-Chief of Behavioural and Cognitive Psychotherapy, the official journal of the British Association for Behavioural and Cognitive Psychotherapy, but does not receive any money in connection with this work. Paul Salkovskis and Hilary Warwick developed cognitive–behaviour therapy for health anxiety but have no financial or other interests in its use. Helen Tyrer has written a book (Tyrer H. Tackling Health Anxiety: A CBT Handbook. London: RCPsych Press; 2013), and Peter Tyrer and Helen Tyrer have co-authored online teaching modules on the recognition and treatment of health anxiety for the Royal College of Psychiatrists. Peter Tyrer is Co-Editor of Personality and Mental Health, for which he receives an annual honorarium.
Last reviewed: May 2016; Accepted: February 2017.
- NLM CatalogRelated NLM Catalog Entries
- Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: a multicentre randomised controlled trial.[Lancet. 2014]Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: a multicentre randomised controlled trial.Tyrer P, Cooper S, Salkovskis P, Tyrer H, Crawford M, Byford S, Dupont S, Finnis S, Green J, McLaren E, et al. Lancet. 2014 Jan 18; 383(9913):219-25. Epub 2013 Oct 18.
- Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.[Health Technol Assess. 2019]Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.Hewlett S, Almeida C, Ambler N, Blair PS, Choy E, Dures E, Hammond A, Hollingworth W, Kadir B, Kirwan J, et al. Health Technol Assess. 2019 Oct; 23(57):1-130.
- Sustained benefit of cognitive behaviour therapy for health anxiety in medical patients (CHAMP) over 8 years: a randomised-controlled trial.[Psychol Med. 2021]Sustained benefit of cognitive behaviour therapy for health anxiety in medical patients (CHAMP) over 8 years: a randomised-controlled trial.Tyrer P, Wang D, Crawford M, Dupont S, Cooper S, Nourmand S, Lazarevic V, Philip A, Tyrer H. Psychol Med. 2021 Jul; 51(10):1714-1722. Epub 2020 Mar 16.
- Review Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT[ 2019]Review Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCTDuffy L, Lewis G, Ades A, Araya R, Bone J, Brabyn S, Button K, Churchill R, Croudace T, Derrick C, et al. 2019 Dec
- Review Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.[Health Technol Assess. 2005]Review Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, Dow MG, Gumley AI. Health Technol Assess. 2005 Nov; 9(42):1-174.
- Cognitive–behaviour therapy for health anxiety in medical patients (CHAMP): a ra...Cognitive–behaviour therapy for health anxiety in medical patients (CHAMP): a randomised controlled trial with outcomes to 5 years
- A multicentre randomised controlled trial and economic evaluation of continuous ...A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT
- A randomised controlled trial of adjunctive triamcinolone acetonide in eyes unde...A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma – the ASCOT study
Your browsing activity is empty.
Activity recording is turned off.
See more...